Benzoate Therapy and Carnitine Deficiency in Non-ketotic Hyperglycinemia
Overview
Authors
Affiliations
Five patients presenting with non-ketotic hyperglycinemia in the neonatal period were treated with sodium benzoate to normalize plasma glycine levels. This therapy resulted in seizure reduction and a marked increase in wakefulness. Plasma carnitine deficiency was noted in three of four patients tested, and benzoylcarnitine was identified in plasma, urine, and CSF. Treatment with L-carnitine normalized plasma free carnitine. L-carnitine showed a tendency to increase the glycine conjugation of benzoate. An episode of coma and increased seizures in one patient was associated with a toxic level of benzoate, probably due to insufficient mobilization of glycine for conjugation. High dose benzoate therapy improved the quality of life of surviving patients. Close monitoring of glycine, benzoate and carnitine levels is advised.
Deep postnatal phenotyping of a new mouse model of nonketotic hyperglycinemia.
Swanson M, Jiang H, Busquet N, Carlsen J, Brindley C, Benke T J Inherit Metab Dis. 2024; 47(5):971-990.
PMID: 38840294 PMC: 11563928. DOI: 10.1002/jimd.12755.
Shelkowitz E, Saneto R, Al-Hertani W, Lubout C, Stence N, Brown M Orphanet J Rare Dis. 2022; 17(1):423.
PMID: 36471344 PMC: 9720968. DOI: 10.1186/s13023-022-02581-6.
Nonketotic Hyperglycinemia: Insight into Current Therapies.
Nowak M, Chuchra P, Paprocka J J Clin Med. 2022; 11(11).
PMID: 35683414 PMC: 9181064. DOI: 10.3390/jcm11113027.
Genotypic and phenotypic features in Turkish patients with classic nonketotic hyperglycinemia.
Bayrak H, Yildiz Y, Olgac A, Kasapkara C, Kucukcongar A, Zenciroglu A Metab Brain Dis. 2021; 36(6):1213-1222.
PMID: 33791923 DOI: 10.1007/s11011-021-00718-3.
Leung K, de Castro S, Santos C, Savery D, Prunty H, Gold-Diaz D J Inherit Metab Dis. 2020; 43(6):1186-1198.
PMID: 32743799 PMC: 8436753. DOI: 10.1002/jimd.12295.